Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

Stopped The decision to withdraw the study was made due to delayed logistics of the supply chain of ceftolozane-tazobactam along with the immense complexities of conducting clinical research felt because of the COVID-19 pandemic.

Conditions

• Bacteremia Caused by Gram-Negative Bacteria

Interventions

• DRUG: Ceftolozane-Tazobactam
• DRUG: Meropenem

Sponsor

The University of Queensland

Collaborators

• [object Object]